Comerica Bank Grows Stock Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Comerica Bank lifted its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 6,515.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 66,746 shares of the company's stock after buying an additional 65,737 shares during the quarter. Comerica Bank's holdings in Hims & Hers Health were worth $1,614,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. SlateStone Wealth LLC grew its position in Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock valued at $257,000 after acquiring an additional 413 shares during the last quarter. Blume Capital Management Inc. raised its position in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares during the period. Summit Investment Advisors Inc. boosted its holdings in Hims & Hers Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock worth $480,000 after acquiring an additional 628 shares during the last quarter. Harbour Investments Inc. raised its holdings in shares of Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock valued at $127,000 after purchasing an additional 833 shares during the last quarter. Finally, Stonekeep Investments LLC increased its holdings in Hims & Hers Health by 5.5% during the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company's stock worth $410,000 after buying an additional 882 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Hims & Hers Health Stock Up 6.3%

Hims & Hers Health stock traded up $3.28 during mid-day trading on Monday, reaching $55.24. 59,181,157 shares of the company's stock traded hands, compared to its average volume of 18,512,327. The company has a market cap of $12.36 billion, a price-to-earnings ratio of 125.54 and a beta of 1.84. The stock has a 50 day moving average of $32.97 and a two-hundred day moving average of $32.51. Hims & Hers Health, Inc. has a 12-month low of $12.07 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. During the same period in the prior year, the business posted $0.05 earnings per share. The business's revenue for the quarter was up 110.7% on a year-over-year basis. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Citigroup restated a "sell" rating and issued a $30.00 price objective (up from $25.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Leerink Partners raised their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research report on Tuesday, February 25th. Piper Sandler restated a "neutral" rating and issued a $39.00 price objective (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Finally, Truist Financial cut their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research report on Thursday, April 10th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of "Hold" and a consensus target price of $37.67.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Melissa Baird sold 67,687 shares of Hims & Hers Health stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $44.71, for a total value of $3,026,285.77. Following the completion of the transaction, the chief operating officer now directly owns 706,872 shares of the company's stock, valued at $31,604,247.12. The trade was a 8.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the transaction, the chief executive officer now directly owns 97,687 shares of the company's stock, valued at $5,692,221.49. This trade represents a 56.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 631,660 shares of company stock valued at $24,978,043 in the last three months. 13.71% of the stock is owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.